Rujirojindakul Pairaya, Aiempanakit Kumpol, Kayasut Kanita, Lekhakula Arnuparp, Sriplung Hutcha
Department of Pathology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla 90110, Thailand.
ISRN Oncol. 2011;2011:670358. doi: 10.5402/2011/670358. Epub 2011 Dec 22.
The aim of this study was to determine the clinical significances of p53 and p-glycoprotein (P-gp) expression on outcome predictors for patients with DLBC. We assessed the immunohistochemical expression of p53 and P-gp using formalin-fixed, paraffin-embedded specimens in 108 patients diagnosed with de novo DLBC. A high expression of p53 was found in 53.7% of the patients. No expression of P-gp was demonstrated in any of the specimens. There were no significant differences in the complete remission (CR) rate (P = 0.79), overall survival (OS) (P = 0.73), or disease-free survival (DFS) (P = 31) between the p53-positive and p53-negative groups. The final model from multivariate analysis that revealed poor performance status was significantly associated with CR (P < 0.001) and OS (P < 0.001). Moreover, the advanced stage was a significant predictor of DFS (P = 0.03). This study demonstrated no impact of the expression of p53 on either response or survival rates.
本研究的目的是确定p53和P-糖蛋白（P-gp）表达对弥漫性大B细胞淋巴瘤（DLBC）患者预后预测指标的临床意义。我们使用福尔马林固定、石蜡包埋的标本，对108例初诊为DLBC的患者评估p53和P-gp的免疫组化表达。53.7%的患者中发现p53高表达。所有标本均未显示P-gp表达。p53阳性组和p53阴性组在完全缓解（CR）率（P = 0.79）、总生存期（OS）（P = 0.73）或无病生存期（DFS）（P = 0.31）方面无显著差异。多变量分析的最终模型显示，较差的体能状态与CR（P < 0.001）和OS（P < 0.001）显著相关。此外，晚期是DFS的显著预测指标（P = 0.03）。本研究表明p53表达对缓解率或生存率均无影响。
